Israeli mapping company ImmunAI partners with AstraZeneca
The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant AstraZeneca for the advanced optimization of clinical trials.
ImmunAI, a pioneering biotechnology company in the field of artificial intelligence (AI) develops the AMICA™ platform - for immune cell mapping, which combines single-cell resolution with the artificial intelligence model of the immune system called the Immunodynamics Engine (IDE). As part of the aforementioned collaboration, AstraZeneca will use the unique platform and machine learning capabilities of ImmunAI to assist in clinical trials in the field of oncology; ImmunAI is expected to receive $18 million for the initial phase.
The multi-year collaboration is based on a previous partnership between the parties that began in 2022 and yielded significant insights for various clinical programs.
ImmunAI, an Israeli-American unicorn that specializes in advanced mapping of the human immune system at cellular resolution, announced a multi-year collaboration with AstraZeneca, one of the world's leading pharmaceutical companies. As part of the agreement, ImmunAI will receive $18 million for the initial phase of the collaboration, which will focus on improving the clinical decision-making process, including optimizing doses, clarifying mechanisms of action, analyzing patient responses and identifying biomarkers, while implementing the artificial intelligence model of the immune system - IDE.
The purpose of the collaboration is to improve the success rates of clinical trials and increase productivity and efficiency in the field of R&D. After this stage, AstraZeneca will be given the opportunity to expand the duration and scope of the collaboration.
Dr. Noam Solomon, CEO of ImmunAI, stated that "This collaboration is a natural continuation of our successful work in promoting the development of drugs in the fields of oncology and immunology. The process of developing a new drug, from the R&D phase to its introduction into the market, is complex, lengthy and expensive. The collaboration with AstraZeneca will allow us to harness our IDE™ artificial intelligence engine to streamline the process and bring potential new treatments to patients."
According to Iker Hvarga, Chief Scientist in the Oncology R&D Department of AstraZeneca, "Artificial intelligence is changing the way we develop cancer drugs and the entire clinical development process. We are pleased to partner with ImmunAI and implement their innovative platform to strengthen our data-driven strategy and uncover new insights into the mechanisms of action of immunotherapies."
About ImmunAI
ImmunAI combines single-cell genomics with machine learning to discover and improve the development of innovative therapies by mapping the human immune system. The company employs approximately 170 employees, of which 85 have advanced degrees (PhD or MD), including experts in genomics, machine learning, bioinformatics, immunology and software engineering. The company has over 30 collaborations with leading pharmaceutical companies from the Fortune 100 and institutions The company's headquarters are located in New York, with branches in Tel Aviv, Zurich and Prague, and so far it has raised close to $270 million.
Jerusalem Post Store
`; document.getElementById("linkPremium").innerHTML = cont; var divWithLink = document.getElementById("premium-link"); if (divWithLink !== null && divWithLink !== 'undefined') { divWithLink.style.border = "solid 1px #cb0f3e"; divWithLink.style.textAlign = "center"; divWithLink.style.marginBottom = "15px"; divWithLink.style.marginTop = "15px"; divWithLink.style.width = "100%"; divWithLink.style.backgroundColor = "#122952"; divWithLink.style.color = "#ffffff"; divWithLink.style.lineHeight = "1.5"; } } (function (v, i) { });